Delgocitinib乳膏在成人中重度慢性手部湿疹中的系统暴露与生物利用度
该研究为开放标签单臂1期试验,纳入16例中重度慢性手部湿疹成人,每日两次外用Delgocitinib乳膏20 mg/g共1周。结果显示系统暴露极低,第1天和第8天几何均值Cmax分别为0.50和0.46 ng/mL,相对口服生物利用度为0.6%,未观察到显著蓄积,耐受性良好。
要点
- Delgocitinib乳膏20 mg/g外用后系统暴露极低,Cmax几何均值≤0.50 ng/mL。
- 相对口服给药生物利用度仅0.6%,提示全身药理作用预期极小。
- 1周内未观察到药物蓄积,试验期间无不良事件报告。
核心结论
- Delgocitinib乳膏20 mg/g在中重度慢性手部湿疹患者中系统暴露极低且耐受性良好,预期无全身药理效应。
研究设计与样本
- 开放标签、单臂1期试验(NCT05486117),纳入16例中重度慢性手部湿疹成人。
- 受试者每日两次外用Delgocitinib乳膏20 mg/g,持续1周,于第1天和第8天进行药代动力学采样。
- 系统暴露与两项健康成人口服Delgocitinib的1期试验(NCT05050279,1.5-12 mg;NBX1-1,1-100 mg)数据进行比较。
主要发现
- 第1天几何均值Cmax为0.50 ng/mL,第8天为0.46 ng/mL。
- 第1天AUC0-12h几何均值为2.5 h*ng/mL,第8天为3.7 h*ng/mL。
- 未观察到Delgocitinib随时间显著蓄积。
- 外用系统暴露显著低于口服给药,相对生物利用度为0.6%。
- 试验期间未报告不良事件。
关键数值与推荐
- Delgocitinib乳膏20 mg/g每日两次外用1周后,几何均值Cmax第1天0.50 ng/mL、第8天0.46 ng/mL。
- AUC0-12h几何均值第1天2.5 h*ng/mL、第8天3.7 h*ng/mL。
- 相对口服生物利用度为0.6%。
临床怎么用
- 对于中重度慢性手部湿疹患者,手掌和手腕外用Delgocitinib乳膏20 mg/g预期不会产生全身药理效应。
- 外用后系统暴露极低,支持其局部用药的安全性特征。
局限性
- 样本量较小(16例),为单臂开放标签设计,未设对照组。
- 仅评估1周用药,长期安全性数据未涉及。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Chronic Hand Eczema (CHE) is a prevalent inflammatory skin condition characterized by pain, pruritus and significant impact on patients' quality of life. Delgocitinib cream, a pan-Janus kinase inhibitor, has shown potential in targeting the key mediators of CHE. To develop a detailed trial drug safety profile, it is vital to assess systemic exposure and bioavailability following repeated drug applications. OBJECTIVES: This analysis aimed to evaluate the systemic exposure and bioavailability of delgocitinib cream 20 mg/g in adults with moderate to severe CHE and compare these parameters with those from oral delgocitinib administration in healthy adults. METHODS: An open-label, single-arm, Phase 1 trial (NCT05486117) was conducted involving 16 adults with moderate to severe CHE. Participants applied delgocitinib cream 20 mg/g twice daily for 1 week. Pharmacokinetic sampling was performed on Day (D)1 and D8. Systemic exposure was compared with data from two Phase 1 trials involving oral delgocitinib in healthy adults (1.5-12 mg, NCT05050279, and 1-100 mg, NBX1-1). RESULTS: Delgocitinib cream demonstrated minimal systemic exposure, with geometric mean maximum plasma concentration (Cmax) values of 0.50 ng/mL on D1 and 0.46 ng/mL on D8. The geometric mean area under the concentration-time curve from 0 to 12 h (AUC0-12h) was 2.5 h*ng/mL on D1 and 3.7 h*ng/mL on D8. No significant accumulation of delgocitinib was observed over time. Systemic exposure with topical application was significantly lower than with oral administration, with a relative bioavailability of 0.6%. Delgocitinib cream was well tolerated, with no reported adverse events during the trial. CONCLUSIONS: Delgocitinib cream shows minimal systemic exposure and is well tolerated in patients with moderate to severe CHE. These findings suggest that no systemic pharmacological effect is expected with the application of delgocitinib cream 20 mg/g to the hands and wrists of patients with moderate to severe CHE. CLINICALTRIALS: gov (or equivalent) listing: NCT05486117, NCT05050279.
引用
- Thaçi D, Gooderham M, Lovato P, et al. Systemic exposure and bioavailability of delgocitinib cream in adults with moderate to severe Chronic Hand Eczema. J Eur Acad Dermatol Venereol. 2025. PMID: 40525591. doi:10.1111/jdv.20777
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。